Exact Sciences stock crashed Wednesday after the company inked a deal for the exclusive eights to Freenome's blood-based ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...

Easy at-home tests for colon cancer, including FIT and Cologuard, offer alternatives to traditional colonoscopies for early detection and prevention.

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) reported Q2 CY2025 results exceeding the market’s revenue ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

Cologuard is easy for patients to use and easy for doctors to interpret the results, said Dr. Casey Allen, a surgical oncologist at Allegheny Health Network in Pennsylvania.

Full-year 2025 revenue and adjusted EBITDA guidance were raised, reflecting strong commercial execution and new product launches. These 10 stocks could mint the next wave of millionaires › Exact ...

A decade ago, Exact Sciences launched Cologuard, impacting the fight against colorectal cancer. Its growth of 7000% is in part due to a focus on consumerization.

Here, two gastroenterologists share their thoughts on Cologuard: Harish Gagneja, MD, gastroenterologist at Austin (Texas) Gastroenterology: I don’t recommend Cologuard as a first-line test because: ...

A 2013 trial of the first iteration of Cologuard, known as DeeP-C, showed the test is 92% sensitive and 87% specific. Put differently, Cologuard returned false positive results 13% of the time in ...

The Cologuard can say that you have an abnormality when a colonoscopy would indicate normal. For 45% of people with a positive Cologuard test, no abnormalities will be found upon colonoscopy.

Unlock URL Order Reprints Gift this Article An image from Cologuard's television ad By Teddy Nykiel – Reporter, Milwaukee Business Journal Mar 2, 2022 Updated Mar 3, 2022 10:26am CST ...